Pay in 4 interest-free payments of $5.76 Learn more
Ships within 48 hours · Estimated delivery Aug 12 - Aug 17
(Read more reviews.) Featured image is from Cymbiotika Natalie Gale is a Boston-based freelance journalist
Phase 2 trial data (Jastreboff et al., NEJM 2023) demonstrated average weight reductions of approximately 1724% over 48 weeks notably higher than currently approved GLP-1 receptor agonists such as semaglutide, though direct comparisons are limited by differences in trial populations and designs
Would definitely recommend this
Boehringer Ingelheim International GmbH Scope of Report GLP-1 Receptor Agonist Market Analysis by Segments Drug: Semaglutide Exenatide Lixisenatide Liraglutide Dulaglutide Others Route of Administration: Oral Parenteral Indication: Diabetes Obesity Others Distribution Channel: Hospital Pharmacies Retail Pharmacies Online Pharmacies Region: North America Latin America Europe Asia-Pacific Middle East & Africa Bibliography Pharmaceutical Executive
US$ 29.05
US$ 23.37
US$ 23.95
US$ 22.41
US$ 23.00
US$ 23.72
US$ 20.09
US$ 24.80
